Newly activated UI Cancer Center Clinical Trials

Newly activated UI Cancer Center Clinical Trials

The following studies have recently been activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office (CTO). Please click on the link to learn about the details regarding the study on clinicaltrials.gov. For more information or questions about a study, please email cancertrials@uic.edu or call 312-355-5112.

A031701: A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients With Muscle-Invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damge Response (DDR) Gene Alterations

Sponsor: Alliance for Clinical Trials in Oncology
Principal Investigator: Ardaman Shergill, MD


NRG-LU003: A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Master Protocol

Sponsor: National Cancer Institute
Principal Investigator: Lawrence Feldman, MD


A031702: A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

Sponsor: National Cancer Institute
Principal Investigator: Ardaman Shergill, MD

 

 

Leave a reply

Your email address will not be published. Required fields are marked *